Texas' top court nixes $32M Vioxx award

Merck ($MRK) won a reversal of the $32 million jury verdict in a Texas case over the Vioxx painkiller. The state's Supreme Court decided that the family of Leonel Garza didn't produce enough evidence to show Vioxx caused his heart attack, thus tossing out the 2006 verdict. Report

Suggested Articles

Pharma

Pushing Your Frontline into a New Frontier

In an era of limited access to key decision makers, how are you mobilizing your field force to communicate the value of your brands and real-world evidence?

Sponsored by EVERSANA
barcelona
Pharma

Novo's Ozempic tops Invokana, Victoza in double head-to-head win

Novo Nordisk’s Ozempic is off to a blazing start, and the company just threw more fuel on the fire with a pair of trial wins.

by Carly Helfand
Roche
Pharma

Biosimilars will leave a $10B gap in Roche's sales: exec

Biosims to Roche's Big 3 cancer drugs will chisel out a $10 billion sales gap by 2023, but newer meds could chip in $16.3 billion, the drugmaker says.

by Angus Liu